KRAS and pancreatic neoplasm: KRAS mutation, being the major driver in PDAC due to its presence in 90–95% of all pancreatic cancer samples, plays a central role to the KRAS pathway in pancreatic cancer development, and is therefore an ideal target for the management of PDAC.